Actress Madeleine Stowe Shares Her Personal Connection to MS in a New Campaign with Genzyme to Educate and Empower the MS Community

Cambridge, MA--(BUSINESS WIRE)--Genzyme, a Sanofi company, announced today that it is collaborating with television and film actress Madeleine Stowe to launch “Lights, Camera, Take Action on MS,” a campaign intended to educate and empower people living with multiple sclerosis (MS) to take action to help manage their disease. Madeleine, who was a care partner to her late father who had MS, will be touring the country to share her personal connection to the disease through a series of in-person and online events.

“I know first-hand the challenges MS can bring to a family, and the amount of strength and support that’s required when facing this disease. That’s why I’ve partnered with Genzyme to provide education and hopefully inspiration to people living with MS and their loved ones,” said Madeleine Stowe. “Through this campaign, I look forward to sharing information to help the MS community take action, whether that is connecting with others, learning something new, or talking to their doctor about treatment options.”

Stowe will participate in a series of live events alongside leading neurologists and people living with MS.  MS patient Teri Evitts is joining Stowe to kick-off the campaign and will share her experience of living with the disease.

“As someone who has been living with MS for 15 years, I know how important it is to keep learning about MS and the resources available to help manage the disease,” said Teri Evitts, who is 36 and lives in Nashville, Tenn., with her husband and 5-year-old son. “I’ve had my ups and downs, but today I feel I’m taking action – being more active, getting exercise and taking time for myself each day.”

The events will take place in the following cities:

  • Chicago, Ill. – December, 6, 2014
  • Orlando, Fla. – January 24, 2015
  • Houston, Tx. – February 7, 2015
  • Live national webcasts on December 6, 2014 and January 24, 2015

“At Genzyme, we understand that there is much more to supporting the MS community than providing treatment,” said Carole Huntsman, Genzyme Vice President and MS Business Unit Head, North America. “We are proud to be launching this new initiative, which is part of our long-term commitment to help improve the lives of people living with MS.”

The “Lights, Camera, Take Action on MS” campaign is one of many resources that Genzyme provides to the MS community. For event registration information or to sign up for a live webcast, visit

Genzyme’s MS One to One® program provides information about multiple sclerosis, treatment, and other relevant resources. MS One to One is available and staffed by dedicated MS nurses and highly trained representatives who can provide support for individuals living with MS, their health care providers, family and loved ones.  For more information about these support services, call the MS One to One line at 1-855-MSOne2One (1-855-676-6326) Monday through Friday, from 8:30am – 8:00pm ET. Information and support are also available at

About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at

Genzyme® and MS One to One® are registered trademarks of Genzyme Corporation.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

Sanofi Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.